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SUMMARY
Introduction: Bioequivalence or compared equivalence studies are used to demonstrate claims that the new product, named
generic product, will have the same bioavailability as the reference product, named brand product. If two products are bioequivalent
it means that they would expect to have the same efficacy and security. Bioequivalence is established by the statistical estimation
of significant differences or not in the pharmacokinetics parameters of area under the curve (AUC) and maximum concentration
(Cmax). In this case, bioequivalence will be evaluated and the bioavailability of Valsartan will be compared. Valsartan is an agent
antihypertensive and specific angiotensin II antagonist acting on the AT1 receptor subtype.
Objective: The aim of this study was to evaluate the bioequivalence of two pharmaceutical products whose active principle
is Valsartan, based on the comparison of the pharmacokinetic measures of rate and extent (in terms of required time) in which
valsartan reaches the sanguineous circulation after a oral dose to 15 volunteers.
Metodology: This was a randomized crossover double blind single-dose study on 15 male healthy volunteers aged between
19 and 28 years. The study was performed in two periods. Each treatment period consisted of a single-dose of 320 mg valsartan,
with a wash-out time of 8 days between the first and second period. Plasma concentrations of valsartan were evaluated by HPLC/
UV with method of addition of valsartan standard and losartan as internal standard.
Results: Valsartan tablets formulation showed this pharmacokinetic parameters: AUC 44,893 µg/mlxh, Cmax 6,430.3 µg/ml and
Tmax 2 h. Valsartan capsules formulation showed this pharmacokinetic parameters: AUC 44,963 µg/mlxh, Cmax 5,831.4 µg/ml and
Tmax 2.5 h.
Conclusion: The study showed no statistically significant differences in the plasma concentration levels after administration
of the two formulations of valsartan: 80 mg tablets and 80 mg capsules. So, the design of the study and the application of the protocols
chosen enabled the demonstration of bioequivalence between the products.
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Estudio comparativo, cruzado, doble ciego, al azar para determinar la bioequivalencia entre dos formulaciones de
valsartán en tabletas y cápsulas
RESUMEN
Introducción: Los estudios de bioequivalencia o equivalencia comparada se realizan para demostrar que el producto en estudio,
conocido como producto genérico, tiene la misma biodisponibilidad del producto de referencia, también conocido como producto
innovador o de marca. Si los dos productos son bioequivalentes, se espera que tengan las mismas características de seguridad
y eficacia. La bioequivalencia es establecida por la estimación estadística de diferencias significativas o no en los parámetros
farmacocinéticos de área bajo la curva (ABC) y concentración máxima (Cmáx). En este caso, se evaluará y se comparará la
biodisponibilidad de valsartán, un agente antihipertensivo inhibidor específico del receptor de angiotensina II subtipo AT1, en las
membranas celulares del músculo liso vascular.
Objetivo: Evaluar la bioequivalencia de dos productos farmacéuticos cuyo principio activo es valsartán, con base en la
comparación de las medidas farmacocinéticas de cantidad y velocidad (en términos de tiempo requerido), con que el valsartán
alcanza la circulación sanguínea después de ser administrado por vía oral a 15 voluntarios.
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Metodología: Se realizó un estudio aleatorizado, cruzado, a
doble ciego, de dosis única en 15 voluntarios sanos con edades
entre 19 y 28 años. El estudio se realizó en dos períodos; en cada
período de tratamiento se administró una dosis de 320 mg de
valsartán, con un período de lavado de 8 días entre el primero y
segundo tratamiento. Las concentraciones plasmáticas se eva-
luaron por HPLC/UV con el método de adición de estándar,
empleando losartán como estándar interno.
Resultados: Para las tabletas de valsartán se obtuvieron los
siguientes parámetros farmacocinéticas: ABC de 44,893 µg/
mlxh, Cmáx de 6,430.3 µg/ml y Tmáx de 2 h. Para las cápsulas de
valsartán se obtuvieron los siguientes parámetros farmaco-
cinéticas: ABC de 44,963 µg/mlxh, Cmáx de 5,831.4 µg/ml y Tmáx
de 2.5 h.
Conclusión: Los resultados del estudio no mostraron dife-
rencias significativas en los niveles de concentraciones
plasmáticas después de la administración de las dos formula-
ciones de valsartán: 80 mg tabletas y 80 mg cápsulas. Por tanto,
el diseño del estudio y la aplicación de los protocolos escogidos
permitieron demostrar la bioequivalencia entre los productos.
Palabras clave: Valsartán; Biodisponibilidad;
Bioequivalencia.
The principle active valsartan is a nonpeptide, orally
active and specific angiotensin II antagonist acting on the
AT1 receptor subtype. Valsartan is a white to practically
white fine powder; it is soluble in ethanol and methanol and
slightly soluble in water.
Valsartan is chemically described as N-(1-oxopentyl)-
N-{[2’-(1H-tetrazol-5-y1)[1,1’-biphenyl]-4-y]methyl}-
Lvaline. Its empirical formula is C 24H29N5O3, its molecular
weight is 435.5, and its structural formula is1:
blocking the binding of angiotensin II to the AT1 receptor
in many tissues, such as vascular smooth muscle and the
adrenal gland. Its action is therefore independent of the
pathways for angiotensin II synthesis2.
Valsartan was the second nonpeptide At-II type 1-
receptor antagonist available for the treatment of hyper-
tension. Valsartan is rapidly absorbed from the gastro-
intestinal tract after oral administration and can be
administered without regard to food intake. The peak
effect of valsartan is evident in two to four hours; the
bioavailability is 25%. Valsartan has a half-life of six to
nine hours and demonstrates antihypertensive effects for
approximately 24 hours. Less than 10% of an orally admi-
nistered dose of valsartan undergoes biotransformation in
the liver; the enzymes responsible for its metabolism are
known, and no active metabolites have been identified.
Elimination occurs primarily in the bile (86%) and to lesser
extent via the kidneys (13%), largely as unchanged drug3.
The tests of bioavailability are based on the application
of concepts with scientific evidence in biological and
pharmaceutical sciences to demonstrate the efficiency of
drugs in giving the substances with pharmacologic activity
that contain, in the waited for amount and the time in
agreement with the design, development and quality
declared by the manufacturer. The tests of bioavailability
are component of the previous tests to the approval like
condition to obtain the sanitary registry of any new drug in
the market and are made during the clinical studies of the
products that contain an active principle never before used
or indicated in certain pathology or a new presentation as
pharmaceutical forms for administration by routes different
from the intravenous. The characterization of the product as
far as its bioavailability, this is, as far as the amount and the
speed of liberation and arrival of the active principle to the
organism, it bases the estimation of the effectiveness properties,
security and quality of the same one as guide who allows to
value the efficiency of the developed product, it facilitates the
comparison of this with other similar products, today more
known like generic drugs, elaborated under different conditions
by types of materials, procedures, productive circumstances
or different surroundings.
The studies to establish bioequivalence (BE) are carried
out to identify significant statistical differences during the
behavior in vivo of pharmaceutical equivalent products,
that they have the same amount of active principle; they
appear in the same form of dosage and fulfill the









N      N
N
N
Angiotensin II is formed from angiotensin in a reaction
catalyzed by angiotensin-converting enzyme (ACE,
kininase II). Angiotensin is the principal pressor agent of
the renin-angiotensin system, with effects that include
vasoconstriction, stimulation of synthesis and release of
aldosterone, cardiac stimulation, and renal reabsoption of
sodium. Valsartan blocks the vasoconstrictor and aldos-
terone-secreting effects of angiotensin II by selectively
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for the check tests of quality to finished products4.
For many products, the comparison is based on the
evaluation of indicative parameters of the bioavailability,
as they are the area under the curve elaborated with the
changes of concentration in a biological fluid, detected
during a period of time, and the maximum concentration
obtained for each product. The studies are applied to drugs
that are administered by non-parenteral routes, where the
innovator or product with which the investigations of
effectiveness and security for the drug were carried out,
it is denominate of «reference» is considered (R), and the
new product to commercialize itself denominates the
product of «test» (T)5.
The demonstration of bioequivalence between products,
by means of an suitable design of investigation, it allows
that the sanitary authority admits the declaration of
substitution and interchangeability among them, during the
dispensation or therapeutic use6.
The aim of this study was to evaluate the relative
bioavaibility of two tablet formulations both containing 80
mg valsartan.
MATERIALS AND METHODS
Volunteers. The study was made in fourteen male
healthy volunteers aged 18-29 years (weight 50-84 kg).
The Ethic Institutional Human Investigations Committee
of CIDEIM reviewed and approved in the corresponding
to fulfillment of the requirements of the World Health
Organization and the Colombian norms, the content of the
protocol of this study and the consent informed which was
obtained after the nature and possible consequences of the
studies were explained.
Chemicals. Valsartan was obtained from USP.
Losartan used as an internal standard was obtained from
Chemo. Acetonitrile (Fisher Scientific) and water was
HPLC grade. Phosphoric acid (Fisher Scientific), methanol
(Panreac), and potassium monobasic phosphate (Merck),
were analytical grade.
Instrumentation and chromatography. Chromato-
graphy was performed with a high-performance liquid
chromatograph LaChrom Elite (Merck-Hitachi) and an
UV detector with diodes array, Chromolith® Performance
RP-18e 100-4.6 mm, 2 µm. Merck, Data station with
EZChrom Elite 3.1.3 software Merck, C8 cartridges Sep-
Vac (100 mg, 1 ml) de Waters. Ohaus Adventurer analytic
balance, Vortex shaker Fisher Scientific, Magnetic shaker
Multistation IKA, Ultrasonic bath Fisher Scientific, Water
bath DIES, Vaccum system Labconco, Vaccum pump
Precision, Ultra Pure Water Productor Simplicity Millipore,
Centrifuge Sorvall RC-5B, Freezer -70ºC Revco, pH
meter WTW Inolab pH 740, solid-phase extraction
equipment Supelco and air compressor Atlas Copco.
DESIGN AND CONDUCTION OF THE STUDY
The study was designed for to evaluate the bioavailability
of the pharmaceutical products identified as valsartan A,
tablets capsules 80 mg, and valsartan B tablets 80 mg, with
base in the pharmacokinetics measures of amount and
velocity (in terms of required time), where upon the
valsartan reaches the sanguineous circulation after being
administered by oral route to fifteen volunteers, in dose of
320 mg of each product, in at random assigned and
separated periods of treatment to each other by an interval
of fifteen days.
CHEMICAL EQUIVALENCE
The samples of products administered to the volunteers
were evaluated previously for the fulfillment of the
physicochemical properties. The results for both samples
allowed to conclude conformity with the applied methods
for: organoleptics characters, dimensions, weight avera-
ge, identification and assay of the active principle, test of
dissolution and uniformity of content. The results of the
evaluation tests verified the fulfillment of the specifications
of the manufacturer for both products and therefore
chemical equivalence between them.
EXPERIMENTAL DESIGN
Study was made of bioequivalence with base in the
compared bioavailability of 320 mg single doses of valsartan
in tablets and capsules administered by oral route, in at
random crossed design of two routes for the product of
test valsartan A, 80 mg capsules, vs. the reference
standard valsartan B, 80 mg tablets, and its dispensation
was in blind for the researchers and volunteers subjects.
The products were administered by random allocation to
fifteen male healthy volunteers aged 19-28 years (weight
60-79 kg).
The study was performed according to a conventional
cross-over experimental design, not replicated, of two
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formulations, in two periods and two sequences, and with
random assignment of the subjects to each treatment, in
order to determine the average values (in arithmetic and
logarithmic scales), and to establish the differences and
ratios, between these average values for the two products
(R and T). The calculations were based on the data
generated for the valsartan analyte in relation to: area
under the concentration curve in time (AUC) between
zero and t and zero and infinite; maximum concentration
achieved (Cmax) and time for maximum concentration.
The products were coded by the Biometry Unit in
CIDEIM as B 80 mg tablets and A 80 mg capsules to
ensure that all participants in the trial (researchers and
subjects alike) remained blind as to which product was
administered at which period to which subject. The
sequences of administration were randomly selected and
the identity of the volunteers was protected by using a
numeric code instead of a name in all the necessary
paperwork.
CLINICAL PROCEDURES
On the day of the study at 7:00 a.m. to each subject was
putt in a heparinized catheter on the an arm vein, then, 15
ml of blood were extracted from each subject and were
labeled as «sample zero»; afterwards, each subject
received one dose corresponding to 320 mg of each
product according to the random order assigned, with 240
ml of dextrose solution 20%, and starting at that moment,
13 more samples (15 ml each) were extracted at the times
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10 and 12 hours. Each
blood sample obtained was labeled before sending it to the
clinical laboratory for the plasma separation and prior to
the physico-chemical analysis. The second assay period
was separated from the first one by 8 days, in order to
assure sufficient elimination of the product already
administered.
ANALYTICAL PROCEDURE
The analytic technique was standardized, validated and
applied to the plasma samples from healthy volunteers
according to the standardized operating procedures code
SOP10033, SOP10044 and SOP10045. The procedure
and technical information related to it are elaborated based
on the industry guides published by the FDA of the United
States, among them the ones described in regulations
21CFR part 58 and 21CFR 320.29, which have details
related to: specificity and minimum limit of quantification.
Calibration curve and linearity. Analyzed in a matrix
with internal standard, with concentrations in the range of
valsartan 50-20000 µg/ml and standard addition of valsartan
2500 µg/ml. Correlation coefficient was 0.9927.
Precision, accuracy and recuperation. The precision
was determined 3 times for every concentration and for 20
concentrations in the range. Specificity was determined
with a precision of 20% and accuracy between 80% and
120%. Recuperation was determined by comparison
between the measurements of the analyte in the sample
and in a standard preparation and it’s was 90%.
The analytical method applied to the determination of
the content of valsartan in plasma samples was developed
based on a methods referenced in the bibliography1,2. The
applied technique was high performance liquid chromato-
graphy (HPLC). The equipment used was a LaChrom
Elite® liquid chromatographer with a diodes array detec-
tor. The analyte was evaluated according to the standardized
and validated procedure, with ultraviolet radiation at 265
nm, solid phase extraction through the use of C8 Sep-Pak
of Waters cartridges and a Chromolith® C18 100 x 4.6 mm
column with 2 mm of particle size; losartan was used as the
internal standard and the mobile phase comprised a mixture
of solvents (acetonitrile-buffer potassium phosphate
(45:55) adjusted to pH 2.7 with acetic acetic glacial); the
separation time of the compounds was 10 minutes.
KINETIC PARAMETERS
Peak plasma concentration (Cmax) and time to peak
(Tmax) were obtained of the plasma concentration-time
curve of valsartan. Area under the plasma concentration
curve AUCo-t was calculated by the trapezoidal rule and
AUCt-inf was calculated by last concentration estimated
and slope of the phase of elimination.
STATISTICAL EVALUATION
The bioequivalence was determinate for the application
of statistic calculations with a confidence interval of 95%
for the difference between the mean values obtained for
the assayed product valsartan A or T (test product) and
valsartan B or R (reference product), in relation to variations
of the area under the concentration-time curve (AUC) and
of the maximum concentration (Cmax) for the studied
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formulations, after the logarithmic transformation of the
data. The antilogarithmic values of the confidence limits
will constitute the interval of 95% for the ratio of the
geometric averages between products A y B, with the
acceptance of a confidence interval of at least 80% and
no more than 125%, through of the applying of the two
applications of test of unilateral hypotheses, defined like:
Ho: ratio between logarithmic averages A/B less or equal
to log(0.8) vs. Ha: ratio between logarithmic averages A/
B greater than log(0.8); Ho: ratio between logarithmic
averages less or equal A/B to log(1.25) vs. Ha: ratio
between logarithmic averages A/B greater than log(1.25)
in order to reject the null hypotheses and to establish the
bioequivalence between products, defined like the
difference between the averages included in the interval
from 0.8 to 1.25 (80% to 125%), with 5% of significance.
The following information required for the pharmaco-
kinetic analyses will be described:
· Plasma concentrations in each time.
· Subject, period, sequence, treatment.
· AUC0-t, AUC0-   , Cmax, Tmax, - Ke y t½
· Inter-individual, intra-individual variability
In addition, the statistical information for ABC0-t,
ABC0-   and Cmax will be obtained, referring to:
· Geometric mean
· Arithmetic mean
· Relation between means
· Confidence intervals
· Logarithmic transformation of measurements to
demonstrate bioequivalence.
RESULTS
The comparison of bioavailability, of the product «test»
(T, code To for this study) and the product «reference»
(R, code B for this study), was made with base in the
values of primary data of valsartan concentration of in the
time, and of the secondary data for the pharmacokinetics
of area under the curve of plasmatic concentrations
between time zero and t. There were statistically no
significant differences between two products (A and B),
for transformed variables AUC (level of significance
0.874), Cmax (level of significance 0.067) and Tmax
(level of significance 0.688) (Table 1, Graphic 1).
The comparison of the values of the pharmacokinetic
parameters or secondary data, calculated with base in the
experimental data for AUC and concentration, by the
application of the non-compartmental model and the ratio
between the values obtained for both products, they show
the bioequivalence between products both, with which the
exposed results are corroborated already (Table 2).
Through of the test of Shapiro-Wilk the normality of the
two variables is confirmed. Test t of twin Student is used.
Were not differences between the concentration average
of products A and B (value p=0.487).
The differences of the values average of Cmax and
AUC, in the primary data and with logarithmic trans-
formation fulfill the criterion of values of significance over
0.05 what allows to establish the significant non difference
between products A and B with a level of 95% confidence.
In the tests of hypothesis for the ratio of the averages
of the primary data and with logarithmic transformation of
AUC and Cmax the null hypothesis was rejected (Ho), in
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Pharmacokinetic analysis of valsartan plasma.
Description of the pharmacokinetic data calculated for
productor reference and test
Kinetic parameter                                    Drug
                                         reference (µg/ml)    test (µg/ml)
AUC(0-t) (µg/ml*h) 44,893 44,963
AUC(t-  ) (µg/ml*h) 232,880 139,0318
Cmax (µg/ml) 6,430.30 5831.40
Tmax (h) 2.0 2.5
Ke (h-1) 0.0881 0.0798
t½ (h) 7.87 8.68
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B less or equal to 80% or 0.8 in data primary or transformed
respectively. And was approved the null hypothesis in the
superior limit of the ratio between the averages of A/B less
or equal 120% or 1.25 in data primary or transformed
respectively. The previous results allow to establish the
significant non difference between products A and B as
far as the valsartan amount of that reaches the sanguineous
circulation and the level of maximum concentration, during
twelve hours after administering an 320 mg dose by oral
route to healthy subjects, with a level of confidence of 95%
and greater significance of 0.05.
DISCUSSION
The analytical results and the statistical analysis of
such base the conclusion of bioequivalence between
products A and B, for the speed and the reached amount
of valsartan in the organism, after being administered in
single doses to 15 healthy volunteers subjects, according
to the experimental design crossed allocation at random of
the treatments and the periods.
The application of the criteria accepted in literature and
the referenced regulation in this study, it demonstrated in the
comparison of products A and B, that the ratio between the
area under the curve of concentration valsartan in the time,
and the ratio between the maximum concentration obtained
with each product, were within the acceptance limits, as much
for the experimental data as for the resultants of its logarithmic
transformation. In agreement with the results of the analytical
determination of the active principle valsartan in the plasma
in 15 volunteers subjects, the results of the statistical and
pharmacokinetic analysis for the comparison, the referenced
guides and regulations that describe to the limits of acceptance
of bioequivalence between drugs and the fulfillment of the
objectives for this study, concludes the bioequivalence between
products A or product in test and product B, or of reference.
CONCLUSION
The design of this study and the application of the
protocols chosen enabled the demonstration of bioequi-
valence between the products Valsartan MK®/valsartan
80 mg capsules from Tecnoquímicas Laboratories and
Diovan®/valsartan 80 mg tablets from Novartis
Laboratories.
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